Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JKB-122 in HCV Non-responders
NCT02293941Phase 2Terminated
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd.
- Start
- May 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of naltrexone in hepatitis C (HCV), sponsored by TaiwanJ Pharmaceuticals Co., Ltd.. Started May 2014; status: terminated.
02
Drugs
naltrexone
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02293941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293941.